Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR vs Surgery in Acromegaly
NCT00225979Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2002
- Primary completion
- Mar 2005
- Modality
- Peptides
01
Overview
Phase 3, randomised, open-label trial of octreotide in acromegaly (2 arms), sponsored by Novartis. Primary endpoint: Mean Growth Hormone and Insulin-like Growth Factor I levels at 48 weeks. Started Nov 2002; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00225979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225979.